Latest Finasteride Stories
MIAMI BEACH, Fla., July 18, 2011 /PRNewswire/ -- Biotech pioneer Divine Skin Inc. (DSKX) announced a partnership with India's largest pharmaceutical company, Ranbaxy Laboratories, to sell the DS Laboratories line of topical hair-growth treatments through its massive distribution pipeline.
NORTH HOLLYWOOD, Calif., July 14, 2011 /PRNewswire/ -- New safety information has been released based on the FDA's review of two large clinical trials: "The Prostate Cancer Prevention Trial "(PCPT) and "Reduction by Dutasteride of Prostate Cancer Events" (REDUCE) trial.
The Oklahoma law firm of Atkins & Markoff and their team of defective drug lawyers hereby announces that it is offering free and confidential initial consultations for people who believe they are suffering from impotence and sexual dysfunction possibly due to Propecia use for hair loss.
HairLoss.com, the Internet's most influential web site dedicated to providing unbiased consumer information about hair loss conditions and hair loss treatments, has introduced a free "hair loss concierge" â„¢ service to its users.
A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.
Prostate cancer is one of the most controversial cancers in both diagnosis and treatment; and with recommendations from several cancer organizations to men with a rapid rise in PSA to immediately have a biopsy for prostate - it only adds to the already heated debate.
Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time â€” known as PSA velocity â€” is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.
Guidelines of several cancer organizations have recommended that men with a rapid rise in PSA have a biopsy for prostate cancer, even if there is no other indication and the PSA is within the "normal" range.
Researchers in France compared 388 men being treated for prostate cancer with 281 healthy men finding that those with the disease were twice as likely as the healthy men to have started losing their hair when they were 20.
Researchers from Boston University School of Medicine (BUSM), in collaboration with colleagues at Lahey Clinic and from Denmark and Germany, have found that 5a-reductase inhibitors (5a-RIs), while improving urinary symptoms in patients with benign prostatic hyperplasia (BPH) and possible hair loss prevention, produces significant adverse effects in some individuals including loss of libido, erectile dysfunction (ED), ejaculatory dysfunction and potential depression.